| 摘要: |
| [摘要] 目前对焦虑障碍缺乏统一的诊断标准，国内外指南的分型和治疗用药不尽相同。一般认为焦虑障碍的一线用药为SSRIs、SNRIs，部分指南推荐普瑞巴林可以作为一线药物，难治性焦虑障碍可在抗抑郁药基础上加二线药物，或者非经典抗精神病药物、抗抽搐药物等，常规治疗时间一般在12~18个月，对于广泛性焦虑障碍(gen eralized anxiety disorder,GAD)甚至需要终身治疗。 |
| 关键词: 焦虑障碍 药物治疗 进展 |
| DOI：10.11724/jdmu.2014.04.22 |
| 分类号: |
| 基金项目: |
|
| Developments in the drug treatment of anxiety disorder |
|
GU Bao-dong 1，FENG Guang-kui 1,TANG Ling-yi 21,2
|
|
1. Neurology,Lianyungang Hospital of Traditional Chinese Medicine, Lianyungang 222004, China;2.2.Nanjing University of Chinese Medicine,Nanjing 210023, China
|
| Abstract: |
| [Abstract] Due to lack of uniform diagnostic criteria, the domestic and international cclassification and treatment guidelines of anxiety disorders vary a lot currently. It is generally recognized that SSRIs and SNRIs are the first-line treatment of anxiety disorders. In addition, a minority of guidelines recommend pregabalin as the first-line drug. Refractory anxiety disorders can be treated by a combination of antidepressants with second-line drugs, non-classical antipsychotics or anti-convulsive drugs. Conventional treatment cycles are generally between 12 to 18 months. Lifelong treatment may be even necessary for GAD. |
| Key words: [Key words] anxiety disorder drug treatment progress |
